Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 34.17% ano a ano.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 2.53B.
Avaliação Justa
O PE mais recente da empresa é 32.96, em uma faixa percentil média de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 24.53M ações, uma redução de 9.12% em relação ao trimestre anterior.
Mantido por John Hussman
O Super Investidor John Hussman possui 7.08K ações desta empresa.